László Horváth

Dr. László Horváth

orcid

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 April 2019 in Frontiers in Neurology
Verified
Journal Article
Open access
LHLászló Horváth
László Horváth
IFIstván Fekete
István Fekete
MMMárk Molnár
Márk Molnár
RVRéka Válóczy
Réka Válóczy
SMSándor Márton
Sándor Márton
KFKlára Fekete
Klára Fekete
Objective: This study was to investigate the outcome of status epilepticus (SE) associated with antiepileptic therapy during SE and in follow-up period, risk factors including age, co-morbidities, pre-existing epilepsy, and etiology in the East-Hungarian region. Methods: A prospective cross-sectional database was compiled from outpatient files between 2013 and 2017. Follow-up ended on 30.06.2018. Results: One hundred and thirty five episodes (male: 68, 50.4%) were evaluated, mean age and follow-up time being 64.1 ± 13.9 years and 39.9 ± 14.2 months, respectively. Of the 89 patients with pre-existing epilepsy, 34 failed to visit the outpatient unit regularly. Case fatality rate was 25.2% and 31 patients (30.7%) died after discharge due to co-morbidities; their mean survival time was 10.44 ± 8 months. Focal, generalized and combined type epilepsies were diagnosed in 67 patients (49.6%), 47 patients (34.8%), and 21 patients (15.6%) of SE, respectively. Nine patients had non-convulsive SE (NCSE). Mean seizure-free period was 6.8 ± 6.9 months. Patients taking carbamazepine (20.9%; OR: 0.37, 95%CI: 0.16–0.82; p = 0.018), levetiracetam (27.5%; OR: 0.51, 95%CI: 0.27–0.97; p = 0.041), or valproate (11.1%; OR: 0.18, 95%CI: 0.05–0.61; p = 0.0043) were expected to achieve seizure freedom after SE. The worst outcome was linked to advanced age, etiology, new onset status epilepticus, NCSE, and focal status epilepsy. Conclusion: This study highlights the importance of regular care and patient follow-up.

22 October 2024 in Polymers
Verified
Journal Article
Open access
PDF file
RARaghad Alsheikh
Raghad Alsheikh
Adam HaimhofferAdam Haimhoffer
Adam Haimhoffer
Dániel NemesDániel Nemes
Dániel Nemes
Zoltán UjhelyiZoltán Ujhelyi
Zoltán Ujhelyi
Pálma FehérPálma Fehér
Pálma Fehér
Dr Bácskay Katalin IldikóDr Bácskay Katalin Ildikó
Dr Bácskay Katalin Ildikó
In situ gels have been developed as an innovative strategy to prolong corneal residence time and enhance drug absorption compared to traditional eye drops. Our study aimed to formulate an ophthalmic in situ gel with a combination of two thermosensitive poloxamers, P407 and P188, in an optimal ratio not only to increase the time of action but also to increase the solubility of selected antibiotics for the treatment of ophthalmic infections. Two BSC II class substances, Azithromycin and Ofloxacin, with different mechanisms of action, have been incorporated into the in situ gel system after determining their solubility. The antibiotics-loaded in situ gel formulation was evaluated for its clarity, pH, rheological properties, and gel characteristics of gelling time, temperature, and capacity. The formulation demonstrated satisfactory clarity, appropriate pH, effective gelation properties in simulated tear fluid, and suitable rheological characteristics. In addition, APIs release insight has been studied through a dissolution test, and the effectivity against sensitive and resistant bacterial strains has been proved through the antimicrobial study. Therefore, our in situ gel system based on thermosensitive poloxamers, with two hydrophobic antibiotics, AZM and OFX, can be considered a valuable approach for ophthalmic drug delivery with an enhancement of the antibiotics bioavailability through increasing the contact time with the ocular surface and enhancing patient compliance.

19 August 2019 in AAPS PharmSciTech
Verified
Journal Article
Open access
PDF file
Gabor VasvariGabor Vasvari
Gabor Vasvari
ÁHÁdám Haimhoffer
Ádám Haimhoffer
LHLászló Horváth
László Horváth
István BudaiIstván Budai
István Budai
GTGyörgy Trencsényi
György Trencsényi
Ferenc FenyvesiFerenc Fenyvesi
Ferenc Fenyvesi
Dosage forms with increased gastric residence time are promising tools to increase bioavailability of drugs with narrow absorption window. Low-density floating formulations could avoid gastric...

15 April 2022 in Cells
Verified
Journal Article
Open access
PDF file
AVAdam Varga
Adam Varga
ÁMÁdám Attila Mátrai
Ádám Attila Mátrai
BBBarbara Baráth
Barbara Baráth
ÁDÁdám Deák
Ádám Deák
LHLászló Horváth
László Horváth
Norbert NemethNorbert Nemeth
Norbert Nemeth
Plasma and blood osmolality values show interspecies differences and are strictly regulated. The effect of these factors also has an influence on microrheological parameters, such as red blood cell (RBC) deformability and aggregation. However, little is known about the interspecies differences in RBC deformability at various blood osmolality levels (osmotic gradient RBC deformability). Our aim was to conduct a descriptive–comparative study on RBC osmotic gradient deformability in several vertebrate species and human blood. Blood samples were taken from healthy volunteers, dogs, cats, pigs, sheep, rabbits, rats, and mice, to measure hematological parameters, as well as conventional and osmotic gradient RBC deformability. Analyzing the elongation index (EI)–osmolality curves, we found the highest maximal EI values (EI max) in human, dog, and rabbit samples. The lowest EI max values were seen in sheep and cat samples, in addition to a characteristic leftward shift of the elongation index–osmolality curves. We found significant differences in the hyperosmolar region. A correlation of mean corpuscular volume and mean corpuscular hemoglobin concentration with osmoscan parameters was found. Osmotic gradient deformability provides further information for better exploration of microrheological diversity between species and may help to better understand the alterations caused by osmolality changes in various disorders.

1 March 2014 in Acta Microbiologica Et Immunologica Hungarica
Verified
Journal Article
Closed access
Renato KovacsRenato Kovacs
Renato Kovacs
ACAnita Czudar
Anita Czudar
LHLászló Horváth
László Horváth
LSLevente Szakács
Levente Szakács
LMLászló Majoros
László Majoros
JKJózsef Kónya
József Kónya
Two Balb/C mouse models of Candida infection were used to detect serum interleukin-6 (IL-6) responses. The first model used systemic infection by Candida albicans ATCC 10231 strain infected through the lateral tail vein of mice without any specific pretreatment. The median Candida burdens of the kidneys were 1.5 x 106 CFU/ml 24 h postinocu lation (p.i.) and 1.2 x 107 CFU/ml 72 h p.i., while median serum IL-6 levels were 479.3 pg/ml and 934.5 pg/ml, respectively. The Candida burden showed significant correlation with serum IL-6 24 h p.i. (R-2 = 0.6358; P = 0.0082) but not 72 h p.i. The second model was a mouse vaginitis model applying intravaginal inoculation of mice pretreated with subcutaneous estradiol-valerate (10 mg/ml) 3 days before infection. Candida cell count in vaginal lavage fluid was 2.8 x 10(6) CFU/ml 24 h p.i. and 1.4 x 10(8) CFU/ml 72 h p.i. Serum IL-6 response was detected in 4 of 15 mice 24 h p.i. and 9 of 15 mice 72 h p.i. Even the responders had low IL-6 serum levels (mean values 29.9 pg/ml and 60.1 pg/ml, respectively) not correlating with Candida cell count in vaginal lavage fluid. In conclusion, serum IL-6 had strong relationship with systemic C. albicans infection while the local C. albicans infection of the vagina led to partial, prolonged and limited serum IL-6 response.

2 March 2017 in International Journal of Clinical Pharmacy
Verified
Journal Article
Closed access
PDF file
LHLászló Horváth
László Horváth
KFKlára Fekete
Klára Fekete
SMSándor Márton
Sándor Márton
IFIstván Fekete
István Fekete